Esperion Historical Income Statement
| ESPR Stock | USD 2.54 0.03 1.17% |
Historical analysis of Esperion Therapeutics income statement accounts such as Gross Profit of 69.4 M or Other Operating Expenses of 285.5 M can show how well Esperion Therapeutics performed in making a profits. Evaluating Esperion Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Esperion Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Esperion Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Esperion Therapeutics is a good buy for the upcoming year.
Esperion |
About Esperion Income Statement Analysis
Esperion Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Esperion Therapeutics shareholders. The income statement also shows Esperion investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Esperion Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Esperion Therapeutics. It is also known as Esperion Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Esperion Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.At this time, Esperion Therapeutics' Interest Expense is relatively stable compared to the past year. As of 11/28/2024, Other Operating Expenses is likely to grow to about 285.5 M, while Gross Profit is likely to drop slightly above 69.4 M.
| 2023 | 2024 (projected) | Interest Income | 4.0M | 3.5M | Reconciled Depreciation | 250K | 432.3K |
Esperion Therapeutics income statement Correlations
Click cells to compare fundamentals
Esperion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Esperion Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.1M | 547K | 612K | 500K | 164K | 90.6K | |
| Interest Expense | 8.1M | 22.7M | 46.4M | 56.8M | 59.0M | 61.9M | |
| Gross Profit | (27.2M) | 225.2M | 64.2M | 48.5M | 73.1M | 69.4M | |
| Other Operating Expenses | 241.5M | 348.9M | 305.2M | 255.0M | 271.9M | 285.5M | |
| Operating Income | (93.1M) | (121.4M) | (226.7M) | (179.5M) | (155.6M) | (147.8M) | |
| Ebit | (93.1M) | (120.9M) | (222.8M) | (176.8M) | (150.3M) | (142.8M) | |
| Research Development | 175.6M | 146.9M | 106.0M | 118.9M | 86.1M | 75.8M | |
| Ebitda | (89.0M) | (120.3M) | (222.1M) | (176.3M) | (150.1M) | (142.6M) | |
| Cost Of Revenue | 175.6M | 2.4M | 14.2M | 27.0M | 43.3M | 49.3M | |
| Total Operating Expenses | 241.5M | 346.6M | 291.0M | 228.0M | 228.6M | 130.2M | |
| Net Income | (109.0M) | (166.2M) | (318.8M) | (287.8M) | (209.2M) | (198.8M) | |
| Income Tax Expense | 11.9M | 22.6M | 49.7M | 54.2M | (3.9K) | (3.7K) | |
| Total Revenue | 148.4M | 227.5M | 78.4M | 75.5M | 116.3M | 110.5M | |
| Income Before Tax | (97.2M) | (143.6M) | (269.1M) | (233.7M) | (209.2M) | (198.8M) | |
| Total Other Income Expense Net | (4.1M) | (22.2M) | (42.4M) | (54.2M) | (53.7M) | (51.0M) | |
| Selling General Administrative | 65.9M | 180.3M | 171.3M | 97.8M | 126.9M | 64.1M | |
| Net Income From Continuing Ops | (97.2M) | (143.6M) | (269.1M) | (233.7M) | (208.4M) | (218.8M) | |
| Non Operating Income Net Other | 4.1M | 515K | 4.0M | 2.7M | 3.0M | 2.3M | |
| Net Income Applicable To Common Shares | (97.2M) | (143.6M) | (269.1M) | (233.7M) | (210.3M) | (220.8M) | |
| Net Interest Income | (8.1M) | (22.7M) | (46.4M) | (56.8M) | (58.2M) | (55.3M) | |
| Reconciled Depreciation | 319K | 547K | 612K | 500K | 250K | 432.3K |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
| 0.9 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Esperion Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.77 | PEPG | PepGen | PairCorr |
| 0.72 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.